New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide
Agreement significantly expands bioAffinity's commercial reach through AvMEDICAL's existing sales team
Service-Disabled Veteran-Owned AvMEDICAL provides access to established government procurement channels
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced it has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB) and established distributor of premium medical-surgical and laboratory services, supplies and equipment to government agencies.
The distribution agreement is expected to strengthen bioAffinity's ability to commercialize CyPath® Lung within the government healthcare market by leveraging AvMEDICAL’s established procurement channels, government contracting expertise and existing customer relationships. bioAffinity and AvMEDICAL will develop co-branded marketing materials, and AvMEDICAL’s sales team will actively promote CyPath Lung to its federal customers, including the U.S. Department of Veteran Affairs (VA).
As an SDVOSB with access to indefinite-delivery, indefinite-quantity (IDIQ) contracts, AvMEDICAL can provide an important advantage for expanding adoption of CyPath Lung across government healthcare systems by simplifying the procurement process. The agreement expands bioAffinity’s commercial reach into the government healthcare supply chain and provides an additional channel for veterans to access CyPath Lung.